Yesterday New York Times Exclude A bomb report About the patent of Moderna’s Covid-19 vaccine. After a four-year partnership with the National Institutes of Health, Moderna rationally applied for a patent for the most important ingredient in her vaccine, and only did so with the names of her own scientists. To the chagrin of the NIH, all of its scientists were excluded from filing patents, which could have major implications. If the government agency is included in the filing, the United States will, in theory, be able to license the technology, which will help it grow faster and wider, including in more developing countries where vaccination rates are lower. If the patent is approved in writing, it will give Moderna sole control over the technology — and potentially billions more. Many in the scientific community see Modern’s move as a betrayal.
Today RE: Wired, With our own veteran writer Marine McKenna Modern CEO, Stephen Bansel, Dr. Nahid Vadelia, MD, MALD, sat down with an internationally recognized infectious-disease physician. Vadelia is the founding director of the Center for Emerging Infectious Diseases Policy and Research at Boston University, as well as the associate director of the National Emerging Infectious Diseases Laboratories (NEIDL), the largest content research facility at BU.
Modern Bansel says he can’t say much about specific patent cases because it’s an open legal matter, but he noted that simply providing the recipe wouldn’t lead to an immediate enough vaccine. “There are no factories around the world waiting to make this product,” Bansel said. Because these factories do not exist. It’s a brand new product. “
Why Moderna is still keeping a close eye on profits, he said, “If you think about it, you need a lot of investment to get innovation to bring products.” As part of Operation Warp Speed, Modern received billions of dollars in funding from the U.S. government for its research, Bansel said, adding that funding for its new vaccine to build production capacity was less forthcoming. When the government and the foundation proved reluctant to invest, the company had to go to the capital market instead of raising about $ 5 billion. He argues that in order to motivate people to invest such money, they generally need to believe that there will be a return on their investment.
From his point of view, Dr. Vadelia does not think that this is a / or situation. He thinks it’s about finding a balance between companies to make sure they’re making a profit so they can continue their research, as well as responding to calls for a global health need during an epidemic that has killed at least 5 million people so far. Vaccine equity is an important component. “There are still parts of the world where only 5 percent of the population has been vaccinated,” he said, adding that while people in the United States are receiving second or third doses and have started vaccinating children before the holidays.